Breaking NewsMedications Hub

FDA Approves WEGOVY (semaglutide) for Cardiovascular Disease Prevention

In a significant stride towards combating cardiovascular disease (CVD), the U.S. Food and Drug Administration (FDA) recently approved WEGOVY (semaglutide), a novel medication demonstrating protective benefits against CVD. This milestone marks a pivotal moment in the pharmaceutical landscape, offering new hope for individuals at risk of this prevalent and potentially life-threatening condition.


Mechanism of Action

WEGOVY (semaglutide), developed by Novo Nordisk, is an injectable prescription medication designed to manage weight by regulating appetite and reducing caloric intake. It mimics the action of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1), which helps regulate appetite, food intake, and blood sugar levels. By activating GLP-1 receptors in the brain, WEGOVY reduces appetite and calorie intake, leading to weight loss. It also slows down stomach emptying, helping control blood sugar levels and potentially contributing to its cardiovascular benefits.


FDA Approves WEGOVY (semaglutide) for Cardiovascular Disease Prevention Heart Matters



The landmark study involved over 17,500 participants aged 45 and older across 41 countries. Tracked for over three years, participants with a BMI of 27 or higher received weekly injections of WEGOVY or a placebo alongside standard heart medications. Results revealed a 20% reduction in the risk of heart attack, stroke, or heart-related death among those receiving WEGOVY compared to the placebo group. Notably, WEGOVY recipients experienced significant weight loss (about 9%) and improvements in key markers of heart disease, including inflammation, cholesterol levels, blood sugars, blood pressure, and waist circumference.


Potential Side Effects

Some potential side effects of WEGOVY (semaglutide) include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, indigestion, fatigue, dizziness, headache, and injection site reactions. More serious side effects like pancreatitis or gallbladder problems may occur. It’s crucial for individuals taking WEGOVY to report any unusual symptoms to their healthcare provider promptly.


FDA Decision

The FDA’s decision to approve WEGOVY (semaglutide) for its protective benefits against CVD highlights the need for innovative approaches in tackling the global burden of cardiovascular disease. Obesity, a significant risk factor for CVD, contributes to conditions such as hypertension, diabetes, and dyslipidemia. WEGOVY can potentially mitigate these risk factors and reduce adverse cardiovascular events. However, individualized treatment plans and carefully considering benefits versus risks are essential.



The FDA’s approval of WEGOVY (semaglutide) represents a significant milestone in the fight against cardiovascular disease. By embracing innovative therapies like WEGOVY, we can work towards a future where CVD is no longer a leading cause of morbidity and mortality. However, it’s crucial to acknowledge potential side effects and prioritize individualized treatment plans, along with lifestyle modifications, to ensure optimal patient outcomes.

Search articles


Subscribe for exclusive heart health resources, valuable tips, and the latest research updates.

Editor's Picks

Empowering heart health

Subscribe to our newsletter and be the first to receive valuable insights, tips, and resources on heart health.

other anti-anginals

When first-line therapies for angina, such as beta blockers, calcium channel blockers, and nitrates, prove inadequate or are not well-tolerated, second-line therapies may be considered.
Perhexiline is a unique medication that enhances the heart's ability to utilize fatty acids for energy, reducing its reliance on oxygen and lowering oxygen demand. This action helps improve blood flow and alleviates chest pain in some patients with refractory angina.
Nicorandil is another second-line option with a dual mechanism of action. It opens potassium channels in smooth muscle cells, causing vasodilation and enhancing coronary blood flow. Additionally, nicorandil also stimulates nitric oxide release, further dilating blood vessels and reducing heart workload.
Trimetazidine is an anti-ischemic agent that improves cardiac efficiency by enhancing glucose metabolism and shifting the heart's energy production to a more oxygen-efficient process. As second-line therapies, these medications offer alternative approaches for managing angina in individuals who do not respond adequately to first-line treatments or those experiencing side effects from other medications.

lipid lowering therapies

Lipid-lowering therapies play a critical role in managing coronary artery disease (CAD), a condition characterized by the narrowing of blood vessels that supply the heart. Among the most commonly discussed and debated classes of medications are statins, which effectively reduce cholesterol levels and are widely prescribed to lower the risk of cardiovascular events. Alongside statins, other medications like ezetimibe, fibrates, and niacin are also utilized to target specific aspects of lipid metabolism, such as cholesterol absorption, triglyceride levels, and raising high-density lipoprotein (HDL) cholesterol. Additionally, the introduction of medications that inhibit PCSK9, an enzyme involved in cholesterol metabolism, has provided a promising new approach to further lower LDL cholesterol levels. These PCSK9 inhibitors, such as Repatha (evolocumab), have shown significant efficacy in reducing LDL cholesterol levels in patients with CAD, especially for those who may not respond well to traditional therapies.


Nitrates are widely used to treat angina and provide quick relief for chest pain. Commonly available in the form of sublingual sprays or tablets, patches, and long-acting tablets, nitrates work by dilating blood vessels, allowing for increased blood flow and reduced resistance. This dilation eases the heart's workload, leading to a decreased demand for oxygen and prompt alleviation of angina symptoms. Sublingual nitrates act rapidly and are often used to provide immediate relief during angina attacks, while patches and long-acting tablets are employed for preventive purposes. However, nitrates may cause side effects such as headaches, dizziness, and flushing, which usually subside over time.

calcium channel blockers

Calcium channel blockers, including amlodipine, felodipine, cardizem (diltiazem), and verapamil, are commonly prescribed for the treatment of angina. These medications work by inhibiting the influx of calcium into the muscle cells of the heart and blood vessels, leading to their relaxation. As a result, blood vessels widen, promoting improved blood flow and reduced blood pressure. In the context of angina, this relaxation decreases the heart's workload, lowering the demand for oxygen and alleviating chest pain. Calcium channel blockers offer a valuable treatment option for individuals with angina, but it is essential to be aware of potential side effects, which may include headaches, dizziness, flushing, and ankle swelling.

Beta blockers

Beta blockers, such as metoprolol, propranolol, atenolol, carvedilol, and bisoprolol, play a crucial role in treating angina. By blocking certain receptors in the heart, they effectively reduce heart rate and the force of contraction, thereby easing the heart's workload. This mechanism of action leads to a decreased demand for oxygen, making beta blockers highly effective in relieving chest pain associated with angina. As with any medication, it's important to consider potential side effects, including tiredness, worsened asthma, erectile dysfunction in some males, and more vivid dreams during sleep. Consult your healthcare provider to determine the suitability of beta blockers for managing your angina and overall heart health.

Anti-platelet Medications

Anti-platelet medications play a crucial role in preventing blood clot formation, reducing the risk of serious cardiovascular events such as heart attacks and strokes. Among the widely used anti-platelet drugs are aspirin, clopidogrel, and ticagrelor.

Aspirin: This well-known medication inhibits platelet activation, making it less likely for platelets to stick together and form clots. Aspirin is commonly used for primary and secondary prevention of heart attacks and strokes.

Clopidogrel: As a potent anti-platelet agent, clopidogrel works by blocking specific receptors on platelets, preventing them from aggregating. It is often prescribed to patients with acute coronary syndrome, those undergoing stent procedures, and for some cases of peripheral arterial disease.

Ticagrelor: Ticagrelor is another effective anti-platelet drug that works by inhibiting platelet activation. It is used in acute coronary syndrome, often given alongside aspirin to reduce the risk of heart-related events.